Physician profile
Surinder Devgun
NPI 1417911231
$69,233.38
in general payments reported to CMS, 2019-2025
39 companies · $21K in 2025
The $21K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,940 · 2020: $8,024 · 2021: $7,365 · 2022: $7,801 · 2023: $2,456 · 2024: $13K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $8,789 · Long Term Medical Supply Or Device Loan: $542 · Travel and Lodging: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,471.00 |
| Food and Beverage | $8,788.92 |
| Long Term Medical Supply Or Device Loan | $542.22 |
| Travel and Lodging | $301.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,617.69 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Phathom Pharmaceuticals, INC. | $22,457.20 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $8,316.50 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,671.90 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pentax of America, INC. | $830.06 | 2020-2024 | Video Colonoscope, Pentax Medical, C2 Cryoballoon |
| Celgene Corporation | $662.30 | 2021-2024 | Zeposia |
| Pfizer INC. | $609.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $508.74 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $449.98 | 2022-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $448.37 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $421.01 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $297.97 | 2022-2025 | Gi Genius |
| Gilead Sciences, INC. | $287.11 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $262.32 | 2019-2024 | |
| Lilly USA, LLC | $239.05 | 2024-2025 | Omvoh |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $235.76 | 2019-2024 | Dificid, Zerbaxa |
| Nestle Healthcare Nutrition INC. | $234.21 | 2021-2023 | |
| Qol Medical, LLC | $199.03 | 2019-2025 | Sucraid |
| Braintree Laboratories, INC. | $178.86 | 2020-2024 | Sutab, Suflave |
| Boston Scientific Corporation | $165.98 | 2022-2024 | Spyglass, Wallflex Duodenal, Agile Esophageal |
| Genzyme Corporation | $135.33 | 2025 | |
| Cook Medical LLC | $120.43 | 2019-2022 | |
| Covidien Lp | $116.41 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $109.38 | 2025 | Iqirvo |
| Ucb, INC. | $107.99 | 2019 | |
| Aimmune Therapeutics, INC. | $95.19 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.79 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $64.81 | 2022-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $64.65 | 2022-2023 | Rebyota |
| Olympus America INC. | $44.67 | 2019 | |
| Concordia Pharmaceuticals INC. | $32.30 | 2019 | |
| Madrigal Pharmaceuticals | $28.91 | 2025 | Rezdiffra |
| Novo Nordisk INC | $28.36 | 2025 | Wegovy |
| Organon LLC | $20.98 | 2024 | |
| Amgen INC. | $19.35 | 2023 | Avsola, Amjevita |
| Capsovision, INC. | $16.92 | 2024 | Capsocam Plus |
| Fujifilm Healthcare Americas Corporation | $16.20 | 2022 | |
| Allergan, INC. | $12.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surinder Devgun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.